Trials / Completed
CompletedNCT02932891
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression.
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS Topical Product in Patients With Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Sun Pharmaceutical Industries, Inc. · Industry
- Sex
- All
- Age
- 6 Months – 17 Years
- Healthy volunteers
- Accepted
Summary
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment with DSXS in Patients with Atopic Dermatitis
Detailed description
To evaluate the potential of DSXS topical product to suppress HPA axis function in patients with moderate to severe atopic dermatitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DSXS topical | topical treatment |
Timeline
- Start date
- 2016-08-01
- Primary completion
- 2017-04-14
- Completion
- 2017-12-12
- First posted
- 2016-10-13
- Last updated
- 2018-12-07
- Results posted
- 2018-12-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02932891. Inclusion in this directory is not an endorsement.